NCI-H1975 / NCI-H1975-luc Orthotopic Mouse Model Service for Lung Cancer

The NCI-H1975 / NCI-H1975-luc orthotopic mouse model of lung cancer carries the canonical EGFR L858R/T790M double-mutant human adenocarcinoma into the lung itself, where thoracic tumors grow on a clinically meaningful timeline and every stage of treatment response — regression, control, escape — is captured quantitatively by luciferase bioluminescence. Alfa Cytology delivers this model as a full preclinical service: authenticated CRL-5908 banking, luciferase line establishment and validation, lung-seeding engraftment in NSG recipients, signal-threshold-triggered randomized dosing, serial in vivo imaging, and endpoints spanning survival, thoracic histopathology, and resistance-marker analysis.

Overview of NCI-H1975 / NCI-H1975-luc Orthotopic Mouse Model for Lung Cancer

NCI-H1975 is a human non-small cell lung adenocarcinoma cell line deposited with ATCC as CRL-5908, isolated in 1988 from a female patient with no smoking history. It carries two EGFR mutations of exceptional clinical significance: the sensitizing L858R substitution in exon 21 and the gatekeeper T790M mutation in exon 20. That pairing reproduces the most common resistance mechanism to first-generation EGFR inhibitors — approximately 60% of patients progressing on erlotinib or gefitinib acquire T790M — and gives the line a precisely defined pharmacology: it is refractory to first-generation agents such as erlotinib and to second-generation inhibitors such as afatinib, yet remains sensitive to third-generation, mutant-selective TKIs including osimertinib and rociletinib (CO-1686), which potently inhibit the L858R/T790M double-mutant kinase at nanomolar concentrations. Beyond the gatekeeper, the line’s resistance repertoire continues to evolve in step with the clinic: chronic osimertinib exposure selects clones acquiring the tertiary C797S mutation or transitioning to an EMT state with AXL upregulation and E-cadherin loss — making NCI-H1975 the standard substrate for mapping the full arc of EGFR-TKI resistance.

Fig 1. In vivo experiments showing that JAC4 alone or combined with AZD9291 (osimertinib) significantly reduced subcutaneous NCI-H1975 tumor volume, downregulated p-EGFR/p-AKT/p-STAT3, and decreased lymph node numbers and lung metastatic burden after tail-vein injection of NCI-H1975 cells, with survival benefit in EGFR-mutant patient cohorts. (Ding, Kun, et al., 2023)

Orthotopically, NCI-H1975-luc cells — engineered with validated luciferase vectors such as RediFect-Fluc-Puromycin lentiviral systems, with STR-confirmed identity after transduction — are delivered intravenously into NSG mice, where circulating tumor cells seed the pulmonary vasculature and establish multifocal lung tumors, with immediate post-injection imaging localizing thoracic signal within the hour. In published orthotopic implementations of this design, treatment begins once the cohort reaches a defined thoracic bioluminescence threshold, erlotinib at high dose merely slows tumor growth while osimertinib at 1-5 mg/kg, dosed five days per week, produces clear tumor-growth inhibition, and adding bevacizumab to osimertinib deepens and prolongs control. Escape is defined operationally — a sustained rise in whole-body photon flux after initial regression — giving sponsors an imaging-native vocabulary for relapse. Together, the model’s T790M gatekeeper biology, its osimertinib responsiveness, its C797S/EMT escape tracks, and its quantitative thoracic readout make the NCI-H1975-luc orthotopic platform the definitive system for benchmarking third-generation TKIs, anti-angiogenic combinations, and resistance-overcoming strategies in EGFR-mutant NSCLC.

Cell Line Information: NCI-H1975 / NCI-H1975-luc

NCI-H1975 is the reference human cell line for T790M-mediated EGFR-TKI resistance research, with a pharmacology validated across thousands of publications. Its luciferase derivative extends it into imaging-guided orthotopic studies. Core attributes follow.

Our Services

What distinguishes an NCI-H1975-luc program is the logic of its controls: the model is only as informative as the pairing of an erlotinib-resistant phenotype with an osimertinib-responsive one, and Alfa Cytology engineers exactly that logic into every study. Authenticated CRL-5908 stocks are expanded at capped passage, luciferase lots are STR-verified and released only after uniform in vitro glow output is demonstrated, and engraftment runs on the published lung-seeding route with threshold-triggered randomization. From first thoracic scan through escape monitoring to final histopathology, Alfa Cytology runs the NCI-H1975 / NCI-H1975-luc orthotopic workflow as a single, accountable preclinical program.

Workflow of NCI-H1975 / NCI-H1975-luc Orthotopic Mouse Model Construction

The NCI-H1975-luc orthotopic workflow is organized around a lung-seeding engraftment route and an imaging-defined treatment trigger — design choices that make response, control, and escape objectively measurable in every animal. The sequence below runs from cell release to final analysis.

1. Authentication and reporter release: NCI-H1975 / NCI-H1975-luc stocks are expanded from authenticated master banks at capped passage, mycoplasma-tested, STR-characterized after transduction, and released only after uniform firefly luciferase expression is confirmed across serial in vitro passages.
2. Inoculum preparation: Log-phase adherent cultures are released with trypsin/EDTA, washed, counted, and resuspended in sterile PBS or serum-free medium at the working dose for tail-vein delivery.
3. Recipient preparation and tail-vein injection: NSG mice are acclimatized, body-weight stratified, and injected via the lateral tail vein using warming and transillumination support; immediate post-injection imaging localizes thoracic signal within the hour, confirming pulmonary seeding.
4. Engraftment monitoring: Thoracic bioluminescence is tracked on a fixed schedule with body weight and clinical scoring, building per-animal growth curves that define when the cohort crosses the predefined treatment threshold.
5. Threshold-triggered randomization and dosing: Once cohort-level thoracic signal reaches the protocol threshold, animals are randomized and dosing begins — osimertinib-class agents at defined schedules, erlotinib-resistant-control arms where designed, or combinations such as osimertinib plus bevacizumab.
6. Response, control, and escape monitoring: Serial imaging resolves regression, sustained control, or escape, with escape defined operationally as a sustained rise in whole-body photon flux across consecutive acquisitions after initial regression.
7. Survival analysis and resistance workup: Morbidity-defined survival feeds Kaplan-Meier analysis; at termination, lungs and thoracic organs are excised, weighed, and imaged ex vivo, histopathology confirms adenocarcinoma involvement, and resistance-status assessment (C797S mutation analysis, EMT-marker immunohistochemistry) is performed where escape was observed.

Fig 2. NCI-H1975 / NCI-H1975-luc orthotopic mouse model construction workflow.

Case Study-NCI-H1975 / NCI-H1975-luc Orthotopic Mouse Model Development

Alfa Cytology has implemented the NCI-H1975-luc orthotopic platform in preclinical programs addressing third-generation EGFR-TKI efficacy, anti-angiogenic combinations, and resistance-overcoming modalities. In these studies, thoracic bioluminescence trajectories distinguished erlotinib-refractory growth from osimertinib-mediated control, threshold-triggered randomization balanced arms at matched disease burden, combination regimens were benchmarked against osimertinib monotherapy, and escape events were captured by operational imaging definitions and later interrogated for C797S or EMT-marker status. Survival data were resolved by Kaplan-Meier analysis with histopathological confirmation of thoracic disease. Program-specific parameters and outcomes are retained as sponsor-confidential deliverables, and representative outlines can be furnished upon request.

Why Choose Alfa Cytology?

T790M biology is unforgiving of weak controls — and richly rewarding when a study’s logic is built correctly. Alfa Cytology’s NCI-H1975-luc service is constructed around that logic, pairing authenticated reagents with imaging-native definitions of response and escape. Sponsors benefit from:

• Authenticated CRL-5908 stocks at capped passage with STR-verified luciferase derivatives.
• The published lung-seeding engraftment route with immediate post-injection thoracic signal verification.
• Threshold-triggered randomization that starts all arms at objectively matched disease burden.
• Built-in resistance-control logic contrasting erlotinib-refractory with osimertinib-responsive phenotypes.
• Operational escape definitions that make relapse measurable and comparable across cohorts.
• Resistance workup capability spanning C797S mutation analysis and EMT-marker immunohistochemistry.
• Single-point study accountability with per-acquisition reporting from seeding through survival analysis.

Contact Us

Developing a third-generation EGFR inhibitor, a resistance-overcoming combination, or an ADC against T790M-positive disease? Contact us to discuss engraftment design, treatment triggers, and escape-monitoring strategy for the NCI-H1975 / NCI-H1975-luc orthotopic platform. Alternatively, reach out to Alfa Cytology for a customized proposal and quotation — our team will return a study design aligned with your mechanism and timeline.

For research use only. Not intended for any clinical use.